Which Mean Arterial Pressure (MAP) Should You Target in a Post–Cardiac Arrest Patient With Hypotension: The 65 mm Hg Floor, the 80–100 Band, and When Higher Fails

The target is a MAP of at least 65 mm Hg for most adults after cardiac arrest, with a common ceiling of 80–100 mm Hg when the patient's perfusion signals are unclear. The 2021 European Resuscitation Council post-resuscitation care guidelines set that framing, and the 2025 American Heart Association focused update endorsed a MAP goal between 65 and 100 mm Hg rather than one fixed number. In practice you treat toward 65 as the floor, push higher only for a reason you can name, and back off if the higher target costs you arrhythmia, bleeding, or pulmonary edema.

What the MAP Number Actually Represents After Return of Spontaneous Circulation

Mean arterial pressure is the time-averaged driving pressure across the cardiac cycle, and clinically it is approximated as one-third of pulse pressure plus two-thirds of diastolic pressure. It is the pressure that actually perfuses the coronary and cerebral beds during the diastolic pause, which is why it matters more than the systolic number on a monitor. After return of spontaneous circulation, cerebral autoregulation is often stunned, so flow becomes more pressure-passive than it should be. That single physiological fact drives every target in this article.

The brain loses its ability to hold flow constant at the usual 60–160 mm Hg autoregulatory plateau for hours to days after arrest. During that window, a MAP of 55 can mean frank cerebral hypoperfusion in one patient while 90 is entirely tolerated in another. Nobody has a bedside test that tells you which patient is which.

Cerebral oxygen extraction fraction is the closest thing anyone has to a personalized readout, and it changed clinical thinking. A 2018 study in Circulation by Jakkula and colleagues used near-infrared spectroscopy-based measures in comatose survivors and found that cerebral oxygen extraction was normal in many patients whose MAP sat near 65, suggesting that routinely forcing everyone higher may not add perfusion.

That nuance matters because higher pressure is not free. The trade-off is between underperfusing the brain and overstressing a post-ischemic myocardium, a fresh coronary stent, or a recently cannulated artery. Treat 65 as the minimum acceptable floor and 100 as the point where you should probably ask why you are still climbing.

Why the 65 mm Hg Floor Is the Number You Can Defend in Court and in the Chart

The 65 mm Hg floor appears in the 2021 European Resuscitation Council guidelines, which recommend targeting a MAP that achieves adequate urine output and normalizes lactate without specifying an exact ceiling. That is a deliberately flexible statement, and it reflects the reality that no large randomized trial has ever shown 65 beats 80 for survival with good neurological outcome. The floor survives because it is the pressure below which organ injury from hypoperfusion becomes common and hard to argue you missed.

The 2025 American Heart Association focused update went slightly further and suggested a target range of 65 to 100 mm Hg for adults after cardiac arrest. That is a range, not a target. Reading it as "aim for 85" is a misuse of the document. The AHA phrasing exists because the evidence base is heterogeneous and because harm appears at both ends of the spectrum.

Mechanically, 65 mm Hg is defensible for a simple reason: it is roughly the threshold below which cerebral blood flow falls off the autoregulatory plateau in a normal brain. Add stunned autoregulation and the margin narrows. A patient sitting at 60 on norepinephrine is not the same organism as a patient sitting at 68, even though both look "borderline normal" on a vitals strip.

Documentation also matters more than people admit. A chart that reads "MAP goal >65 mm Hg per post-arrest protocol" is a coherent defense. A chart that reads "pressors titrated to effect" with no number is an invitation for a reviewer to conclude you had no target at all. Name the floor in the order set.

Where the 80–100 mm Hg Band Comes From and What It Buys

The upper band of 80–100 mm Hg comes from the 2025 AHA recommendation and from two trials that tried to answer the question head-on. The BOX trial, published in Circulation in 2022 by Kjaergaard and colleagues, randomized 789 comatose survivors to a MAP of 63 versus 77 mm Hg. The primary composite of death or severe disability at 90 days came in at 34 percent in the low-target group and 32 percent in the high-target group. That is not a difference. It is a null.

The NEUROPROTECT trial, published in JAMA Neurology in 2022 by Ameloot and colleagues, compared a MAP of 85–100 with 65 in a smaller French cohort and also failed to show a neurological benefit. Both trials are the reason guideline writers now hedge rather than sloganize. Higher pressure does not rescue the brain on average.

What the band does buy you is a buffer against the frequent dips during transport, suctioning, turning, and dialysis hookup. A patient titrated to sit at 68 has no reserve when a nurse rolls them and the MAP drops to 52 for ninety seconds. A patient sitting at 85 has room to wobble. That buffer is a legitimate reason to aim higher than the floor in a patient whose provocations are frequent.

The band also carries a cost you must be ready to name. In the BOX trial, the higher target group required more vasoactive support and had more episodes of bradycardia. Pressor exposure is not benign, and the dose of norepinephrine is itself associated with worse outcomes in observational data. Climbing to 90 earns you stability and buys you an arrhythmia risk and a higher pressor load. Name which one you want before you start titrating.

Reading the Neuromonitoring at the Bedside When You Cannot Randomize the Patient

In the real world you make the target decision patient by patient with imperfect tools, and there are three usable signals. The first is cerebral oxygen extraction as measured by near-infrared spectroscopy, which is portable enough to use in an ICU but not yet standard of care. The second is the combination of urine output and lactate clearance, which tells you whether the target is working at the body level. The third is the pupil exam, which is crude but free.

A rising lactate with a MAP of 67 suggests the floor is not the right floor for this patient. A patient whose lactate is clearing and whose urine output is running above 0.5 mL/kg/hr at a MAP of 66 probably does not need to be pushed higher. That logic is not from a randomized trial. It is from the 2021 ERC emphasis on targeting organ-perfusion endpoints rather than a single pressure number.

Near-infrared spectroscopy is the most interesting tool in the space, and it is also the most oversold. Jakkula's work suggested cerebral oxygen extraction stays normal across a wide MAP range in many comatose survivors, which means the brain may not need the pressure you assume it does. Using an NIRS value to justify a higher target is defensible. Using it to justify a lower target requires more caution, because the technology has not been validated for that decision.

If you have none of those three signals, treat to 65 and watch the trend rather than the snapshot. A single MAP value from a wave artifact is not a data point. Two hours of a moving average is.

Building the Vasopressor Order Set That Matches the Target

The order set should start with norepinephrine as first-line because the 2020 AHA advanced cardiovascular life support adult cardiac arrest algorithm and the posterior-circulation literature both support it as the agent with the most reliable MAP response and the least arrhythmogenicity. Norepinephrine is titrated in mcg/min or mcg/kg/min, and the target MAP is written at the top of the order, not buried in the titrate-to-effect line.

Use the table below as a practical comparison of what the common agents do when the MAP target is already written.

The decision rule is short. Write 65 as the floor, write 100 as the ceiling, and write "do not escalate above 85 without a documented perfusion deficit" in the order set. That last line is what prevents a night-shift intern from chasing 95 on a patient whose lactate is flat and whose brain is asleep on propofol.

Failure handling deserves its own line in the order set. If the patient cannot hold a MAP of 65 on norepinephrine at 0.5 mcg/kg/min, you are not looking at a target problem. You are looking at a volume problem, a pump problem, or a mechanical problem. Escalating the MAP target hides all three, and none of them are fixed by higher numbers on the monitor.

When Chasing 85 Hurts More Than It Helps

The failure scenarios are concrete and they show up on most post-arrest ICU rotations. A 62-year-old with a fresh drug-eluting stent in the LAD gets pushed to a MAP of 90 to "protect the brain," and the increased wall stress and catecholamine load produce recurrent ventricular tachycardia at hour six. The brain gets a pressure it did not need and the heart gets an insult it cannot afford.

A second failure case is the post-arrest patient after a long downtime who has a stunned myocardium with an ejection fraction of 20 percent. Pushing to 85 on norepinephrine raises afterload and increases myocardial oxygen demand in a heart that is already failing. That patient often does better with inotrope support and a lower MAP target, and the decision should be made by the intensivist or cardiologist rather than by a protocol.

The third case is the patient with a traumatic or hemorrhagic cause of the arrest who is now on dual antiplatelet therapy or a heparin infusion. Every extra millimeter of mercury on a fresh groin cannulation site is bleeding risk with no neurological benefit if the brain is already dead by exam. A target of 65 with careful monitoring is the defensible choice, and the reasoning should be documented.

A fourth failure is the patient who is autoregulating fine but whose monitor is wrong. Arterial line damping from a kinked tubing produces a MAP of 58 when the true value is 70. Not every low number is a real low number. Before you increase the pressor, check the waveform.

How the Target Changes With Cause of Arrest, Temperature, and Transport

The cause of arrest should modify your target, and the guidelines build in room for that. A patient after an asphyxial arrest with hypoxic-ischemic encephalopathy may benefit from a MAP closer to the high end of the band because the brain injury is diffuse and the perfusion signal is worse. A patient after a witnessed VF arrest with a bystander and a quick shock has a much smaller ischemic burden and tolerates a lower target without argument.

Targeted temperature management changes the math. The 2021 ERC guidelines support TTM at 32–36°C, and hypothermia raises systemic vascular resistance and slows the heart rate, which changes how much vasopressor you need for the same MAP. A patient who needs not a single pressor dose at 36.5°C may need 0.08 mcg/kg/min of norepinephrine at 33°C. Titrating to the same MAP number across both temperatures is reasonable, but expect the dose to change.

Transport is the fourth modifier. During a ground or air transfer, the MAP routinely dips 10–15 mm Hg from motion artifact and from the change in the monitoring setup. A patient sitting at 75 before departure has a cushion for that dip. A patient sitting at 66 does not. If you know a transfer is imminent, aim for the middle of the band and accept the higher pressor dose as the cost of arrival.

None of these modifiers overrules the floor. They only change where in the 65–100 band you decide to sit. And if the patient's cause and temperature push you in opposite directions, the perfusion marker wins. Lactate and urine output are the arbitration rules.

What the Clinical Trials Actually Showed About Higher Targets

The trial record is small and it points in the same direction, which is why the guideline language is so careful. Three randomized comparisons matter: BOX, NEUROPROTECT, and the earlier COMACARE pilot published in Intensive Care Medicine in 2018 by Jakkula and colleagues, which compared 65 with 80 mm Hg and found no difference in neuron-specific enolase or cerebral oxygen extraction.

The table below sets out what each trial asked and what it found.

Read the table as a whole and one conclusion holds: no trial has shown a higher target improves survival with good neurological outcome. That is not the same as showing higher pressure is harmful. It shows that if there is a benefit, it is small enough that a few hundred patients could not detect it, and it is certainly not a benefit you can promise a family at the bedside.

The COMACARE result deserves a mention because it used a biomarker rather than a functional outcome. Neuron-specific enolase at 48 hours did not differ between the 65 and 80 groups, which cuts against the idea that the brain is starving at 65 in most patients. The BOX trial's higher-target group needed more vasoactive support, which is the harm side of the ledger.

When you write the target, cite the number the guidelines give you, not a specific trial. Guidelines integrate the trials. A single trial does not.

The Edge Cases That Break Every Simple Target

A pediatric patient is the most obvious edge case, and the guidelines do not give a single MAP target for children. Pediatric MAP targets are age-based, and the 2020 AHA pediatric post-arrest care guidance instead emphasizes age-appropriate blood pressure for age along with perfusion markers. Applying 65 to a two-year-old is a mistake with a plausible-sounding justification.

Pregnancy is a second edge case. A pregnant patient after arrest has a uterus that compresses the inferior vena cava after 20 weeks, and the MAP target may be unreachable until you perform a left lateral tilt. No amount of norepinephrine will fix a mechanical obstruction. Fix the positioning before you escalate the target.

Patients on venoarterial ECMO after arrest are a third edge case, and this is where the MAP number becomes genuinely unreliable. On peripheral VA-ECMO, the MAP you read is a blend of native cardiac output and ECMO circuit flow. A MAP of 65 on the monitor may not reflect cerebral perfusion, and a MAP of 55 may be perfectly adequate if the native ejection is contributing. The target should come from the ECMO team and the cerebral oximetry trend, not from a protocol.

A fourth edge case is the patient with chronic hypertension. The autoregulatory curve shifts upward in long-standing hypertension, and a patient whose baseline MAP is 110 may genuinely need a higher target than 65 to maintain cerebral flow. The evidence for this is observational and it is not in the guidelines as a specific number. It is a reason to lift the floor by 10 to 15 mm Hg in patients with a documented high baseline, and it is a reason to document why.

FAQ

Is a MAP of 65 enough after cardiac arrest?

For most adults, yes, and the 2025 American Heart Association focused update treats 65 as the bottom of an acceptable 65–100 mm Hg range. The floor is chosen because it sits near the lower edge of cerebral autoregulation in a normal brain. A patient who holds 65 with normal lactate clearance and adequate urine output does not need escalation. If either marker is abnormal, that is the signal to move up the band.

Should I target 85 mm Hg because higher is safer for the brain?

No, because the two largest randomized trials found no neurological benefit from a higher target. BOX compared 63 with 77 mm Hg across 789 patients and reported 34 percent versus 32 percent death or severe disability, a difference consistent with chance. NEUROPROTECT found the same null result at 85–100 versus 65. Higher pressure is a buffer, not a treatment.

What if the MAP will not reach 65 on high-dose norepinephrine?

That is a mechanical or volume problem, not a target problem, and the first step is to check the arterial waveform for damping and confirm the reading with a second site. Then look for untreated causes: hypovolemia, tamponade, tension pneumothorax, ongoing ischemia, or a missed hemorrhage. Escalating beyond 0.5 mcg/kg/min of norepinephrine without fixing the cause buys a number and loses the patient.

Does targeted temperature management change the MAP target?

The target range does not change, but the vasopressor dose required to hit it usually does. Hypothermia at 33°C raises systemic vascular resistance and slows the heart rate, so a patient who needed 0.05 mcg/kg/min at 36.5°C may need 0.08 mcg/kg/min at 33°C for the same MAP. Titrate to the same number and expect the dose to move.

How does VA-ECMO change what the MAP number means?

On peripheral venoarterial ECMO, the arterial line reading blends native cardiac ejection with circuit flow, so the MAP can misrepresent cerebral perfusion in either direction. A reading of 55 may be adequate if native output is contributing, and a reading of 65 may be low if the native ejection is poor. Let the ECMO team set the target and trend cerebral oximetry rather than relying on the number alone.

Can I use near-infrared spectroscopy to pick a higher target?

You can use it as supporting evidence, but not as the sole justification. Jakkula's 2018 work in Circulation showed that cerebral oxygen extraction stays normal across a wide MAP range in many comatose survivors, which suggests the brain does not always need the higher pressure. NIRS is not validated for deciding to lower a target. It is defensible for documenting why you chose to sit at 80 instead of 65.

What MAP should I target in a patient with chronic hypertension?

Lift the floor by roughly 10 to 15 mm Hg in patients with long-standing, well-documented hypertension, because their autoregulatory curve is shifted upward. There is no randomized trial defining the exact number, so document the baseline blood pressure and the reasoning. The guideline range of 65–100 still applies as a ceiling, and the perfusion markers still arbitrate.

Does the cause of arrest change the target within the 65–100 range?

It can. A patient after an asphyxial arrest with diffuse hypoxic-ischemic injury may warrant sitting near the high end of the band, while a patient after a witnessed VF arrest with a short downtime usually tolerates the floor. Neither modifier overrides the perfusion markers, and neither justifies exceeding 100 mm Hg without a specific, documented reason.

This article is general educational information about post–cardiac arrest hemodynamic targets and is not a diagnosis, treatment plan, or substitute for local protocol. Institutional order sets, the treating intensivist, and current resuscitation guidelines govern the actual target for any individual patient. For immediate clinical deterioration or emergency care decisions, contact local emergency services and the on-call critical care team.